These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34467985)

  • 21. Effective virus-neutralizing activities in antisera from the first wave of survivors of severe COVID-19.
    Han Y; Liu P; Qiu Y; Zhou J; Liu Y; Hu X; Yang Q; Huang R; Wen X; Song H; Yu P; Yang M; Zhang J; Liu WJ; Peng K; Wu G; Zhang D; Zhou X; Wu Y
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33476301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution of antibody immunity to SARS-CoV-2.
    Gaebler C; Wang Z; Lorenzi JCC; Muecksch F; Finkin S; Tokuyama M; Cho A; Jankovic M; Schaefer-Babajew D; Oliveira TY; Cipolla M; Viant C; Barnes CO; Bram Y; Breton G; Hägglöf T; Mendoza P; Hurley A; Turroja M; Gordon K; Millard KG; Ramos V; Schmidt F; Weisblum Y; Jha D; Tankelevich M; Martinez-Delgado G; Yee J; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Robbiani DF; Zhao Z; Gazumyan A; Schwartz RE; Hatziioannou T; Bjorkman PJ; Mehandru S; Bieniasz PD; Caskey M; Nussenzweig MC
    Nature; 2021 Mar; 591(7851):639-644. PubMed ID: 33461210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
    Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
    EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases.
    Castillo-Olivares J; Wells DA; Ferrari M; Chan ACY; Smith P; Nadesalingam A; Paloniemi M; Carnell GW; Ohlendorf L; Cantoni D; Mayora-Neto M; Palmer P; Tonks P; Temperton NJ; Peterhoff D; Neckermann P; Wagner R; Doffinger R; Kempster S; Otter AD; Semper A; Brooks T; Albecka A; James LC; Page M; Schwaeble W; Baxendale H; Heeney JL
    Front Immunol; 2021; 12():748291. PubMed ID: 34867975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
    Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G
    Front Immunol; 2021; 12():778679. PubMed ID: 34868051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients.
    Mohn KG; Bredholt G; Zhou F; Madsen A; Onyango TB; Fjelltveit EB; Jalloh SL; Brokstad KA; Cantoni D; Mayora-Neto M; Temperton N; Langeland N; Cox RJ;
    PLoS One; 2022; 17(2):e0261979. PubMed ID: 35192617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T follicular helper cells in the humoral immune response to SARS-CoV-2 infection and vaccination.
    Koutsakos M; Lee WS; Wheatley AK; Kent SJ; Juno JA
    J Leukoc Biol; 2022 Feb; 111(2):355-365. PubMed ID: 34730247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses.
    Balachandran H; Phetsouphanh C; Agapiou D; Adhikari A; Rodrigo C; Hammoud M; Shrestha LB; Keoshkerian E; Gupta M; Turville S; Christ D; King C; Sasson SC; Bartlett A; Grubor-Bauk B; Rawlinson W; Aggarwal A; Stella AO; Klemm V; Mina MM; Post JJ; Hudson B; Gilroy N; Konecny P; Ahlenstiel G; Dwyer DE; Sorrell TC; Kelleher A; Tedla N; Lloyd AR; Martinello M; Bull RA;
    Cell Rep; 2022 Feb; 38(6):110345. PubMed ID: 35090598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.
    Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM
    Front Immunol; 2021; 12():742914. PubMed ID: 34659237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistence assessment of SARS-CoV-2-specific IgG antibody in recovered COVID-19 individuals and its association with clinical symptoms and disease severity: A prospective longitudinal cohort study.
    Moradi G; Mohamadi Bolbanabad A; Ahmadi S; Aghaei A; Bahrami F; Veysi A; Nasiri Kalmarzi R; Shokri A; Ghaderi E; Mohsenpour B; Mohammadi A
    Int Immunopharmacol; 2021 Sep; 98():107893. PubMed ID: 34174700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term monitoring of the development and extinction of IgA and IgG responses to SARS-CoV-2 infection.
    Ivanov A; Semenova E
    J Med Virol; 2021 Oct; 93(10):5953-5960. PubMed ID: 34185312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.
    Fendler A; Shepherd STC; Au L; Wilkinson KA; Wu M; Byrne F; Cerrone M; Schmitt AM; Joharatnam-Hogan N; Shum B; Tippu Z; Rzeniewicz K; Boos LA; Harvey R; Carlyle E; Edmonds K; Del Rosario L; Sarker S; Lingard K; Mangwende M; Holt L; Ahmod H; Korteweg J; Foley T; Bazin J; Gordon W; Barber T; Emslie-Henry A; Xie W; Gerard CL; Deng D; Wall EC; Agua-Doce A; Namjou S; Caidan S; Gavrielides M; MacRae JI; Kelly G; Peat K; Kelly D; Murra A; Kelly K; O'Flaherty M; Dowdie L; Ash N; Gronthoud F; Shea RL; Gardner G; Murray D; Kinnaird F; Cui W; Pascual J; Rodney S; Mencel J; Curtis O; Stephenson C; Robinson A; Oza B; Farag S; Leslie I; Rogiers A; Iyengar S; Ethell M; Messiou C; Cunningham D; Chau I; Starling N; Turner N; Welsh L; van As N; Jones RL; Droney J; Banerjee S; Tatham KC; O'Brien M; Harrington K; Bhide S; Okines A; Reid A; Young K; Furness AJS; Pickering L; Swanton C; ; Gandhi S; Gamblin S; Bauer DLV; Kassiotis G; Kumar S; Yousaf N; Jhanji S; Nicholson E; Howell M; Walker S; Wilkinson RJ; Larkin J; Turajlic S;
    Nat Cancer; 2021 Dec; 2(12):1305-1320. PubMed ID: 35121899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination.
    Cagigi A; Yu M; Österberg B; Svensson J; Falck-Jones S; Vangeti S; Åhlberg E; Azizmohammadi L; Warnqvist A; Falck-Jones R; Gubisch PC; Ödemis M; Ghafoor F; Eisele M; Lenart K; Bell M; Johansson N; Albert J; Sälde J; Pettie DD; Murphy MP; Carter L; King NP; Ols S; Normark J; Ahlm C; Forsell MN; Färnert A; Loré K; Smed-Sörensen A
    JCI Insight; 2021 Nov; 6(22):. PubMed ID: 34665783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
    Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
    Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11 Months Following Infection.
    De Giorgi V; West KA; Henning AN; Chen LN; Holbrook MR; Gross R; Liang J; Postnikova E; Trenbeath J; Pogue S; Scinto T; Alter HJ; Cantilena CC
    J Infect Dis; 2021 Oct; 224(8):1294-1304. PubMed ID: 34089610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Durable SARS-CoV-2 B cell immunity after mild or severe disease.
    Ogega CO; Skinner NE; Blair PW; Park HS; Littlefield K; Ganesan A; Dhakal S; Ladiwala P; Antar AA; Ray SC; Betenbaugh MJ; Pekosz A; Klein SL; Manabe YC; Cox AL; Bailey JR
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33571162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity.
    Trinité B; Tarrés-Freixas F; Rodon J; Pradenas E; Urrea V; Marfil S; Rodríguez de la Concepción ML; Ávila-Nieto C; Aguilar-Gurrieri C; Barajas A; Ortiz R; Paredes R; Mateu L; Valencia A; Guallar V; Ruiz L; Grau E; Massanella M; Puig J; Chamorro A; Izquierdo-Useros N; Segalés J; Clotet B; Carrillo J; Vergara-Alert J; Blanco J
    Sci Rep; 2021 Jan; 11(1):2608. PubMed ID: 33510275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis.
    Lee E; Oh JE
    Mol Cells; 2021 Jun; 44(6):392-400. PubMed ID: 34059562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection.
    Havervall S; Jernbom Falk A; Klingström J; Ng H; Greilert-Norin N; Gabrielsson L; Salomonsson AC; Isaksson E; Rudberg AS; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Christ W; Olausson M; Hedhammar M; Tegel H; Mangsbo S; Phillipson M; Månberg A; Hober S; Nilsson P; Thålin C
    PLoS One; 2022; 17(1):e0262169. PubMed ID: 35020778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.